SMBC Nikko analyst David Hoang downgraded Provention Bio (PRVB) to Neutral from Outperform with a price target of $25, up from $15, after Sanofi (SNY) agreed to acquire Provention Bio for $25 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PRVB:
- Provention Bio downgraded to Neutral from Overweight at Cantor Fitzgerald
- Provention Bio cancels Q4, FY22 earnings release, conference call
- Provention Bio Soars after Acquisition by Sanofi for $2.9 Billion
- Sanofi acquires Provention Bio for $25 per share or $2.9B
- Provention Bio management to meet virtually with Oppenheimer